Colorado PDMP Task Force Annual Reports

- Statutory Requirements
 - PDMP Task Force
- * Annual Report Topics Each Year
- Where to Find Annual Reports
- CO PDMP Contact Information

Presented by: Justin Wipf, MA Program Analyst, Colorado PDMP

PDMP TTAC Administrators National Meeting San Antonio, TX May 8, 2024



Colorado PDMP Task Force Annual Reports

Colorado PDMP first authorized in 2005, went live in 2007

PDMP is under CO Board of Pharmacy, Division of Professions & Occupations, Department of Regulatory Agencies (DORA)

2014 - Substantial updates to Colorado PDMP (HB14-1283)

- Registration mandate for pharmacists and DEA-licensed prescribers
- Delegate access
- Department of Public Health and Environment access
- Unsolicited reports
- Requirement to create a PDMP Task Force and submit an Annual Report to the Department of Regulatory Agencies (DORA) Executive Director and Colorado General Assembly



CO PDMP Task Force and Annual Report

Examination and analysis of PDMP - recommendations to DORA Executive Director

2014 Requirements:

DORA Executive Director shall create a PDMP Task Force to develop a strategic plan to reduce prescription drug abuse in order to:

- 1) Examine issues, opportunities, and weaknesses of the program, including how personal information is secured in the program and whether inclusion of personal identifying information in the program and access to that information is necessary.
- 2) Make recommendations to the Executive Director on ways to make the program a more effective tool for practitioners and pharmacists in order to reduce prescription drug abuse in Colorado.

The Task Force is required to submit Annual Reports to the Executive Director and the General Assembly detailing its findings and recommendations.



PDMP Task Force

PDMP Task Force: PDMP Work Group at the Colorado Consortium for Prescription Drug Abuse Prevention

Formed in 2013, the Colorado Consortium for Prescription Drug Abuse Prevention coordinates Colorado's response to the misuse of medications such as opioids, stimulants, and sedatives. The Consortium's mission is to reduce prescription drug misuse and abuse in Colorado by developing policies, programs, and partnerships with the many state agencies, organizations, and community coalitions addressing one of Colorado's major public health crises.

The Consortium works with state and federal agencies, task forces, nonprofit organizations, health care providers, public health officials, and other groups that address the opioid epidemic. This group works to improve education, public awareness, research, safe disposal, harm reduction, treatment, and recovery across the state.

The Consortium also provides expertise to policymakers about legislation and programming that can be implemented to address the crisis.

13 full-time staff

CORXCONSORTIUM.ORG



CO Center for Prescription Drug Abuse Prevention

Colorado Center for Prescription Drug Abuse Prevention

Formed in 2017, the Center for Prescription Drug Abuse Prevention is housed at the Skaggs School of Pharmacy and Pharmaceutical Services at the University of Colorado Anschutz Medical Campus. The Center hosts the Consortium and facilitates interdisciplinary research, identifies and promotes evidence-based clinical practices, educates health care and public health practitioners, and tests, implements, and promotes new models of care for the treatment of pain and substance use disorders.

The Consortium also provides expertise to policymakers about legislation and programming that can be implemented to address the crisis.



Consortium for Prescription Drug Abuse Prevention

Consortium Work Groups and Structure







PDMP Task Force

PDMP Work Group Co-Chairs

Dmitry Kunin, PharmD, MBA (2019 - present) Senior Program Director for Colorado State Board of Pharmacy and PDMP at DORA Division of Professions and Occupations

Dr. Jason Hoppe, DO (2014 - present) University of Colorado Department of Emergency Medicine

200+ members



Due July 1 Annually since 2016

Posted to Colorado General Assembly website

www.leg.state.co.us/library/reports.nsf/reports.xsp

Statutory Citation: 12-280-409(2)



2016

Task 1: What specific steps can Colorado take to integrate the PDMP into Colorado's two health information exchanges and electronic health records?

Task 2: What metrics and statistics should DORA track to ensure the PDMP is as effective a public health tool as possible?



2017

Task 1: Develop recommendations concerning how the Task Force can assist Colorado's two regional HIEs in their goals to complete two pilot EHR integrations into hospitals by fall 2017.

Task 2: Study any other available methods of PDMP integration with a focus on the population of prescribers who fall outside of HIE and EHR integration opportunities.



2018

Task 1: Develop recommendations concerning methods for measuring the Colorado PDMP's effectiveness in terms of opioid prescriber behavior outside of PDMP utilization.

Task 2: Develop recommendations concerning the potential use of PDMP Scorecards.



2019

Task 1: Continue developing recommendations concerning specific metrics for measuring PDMP effectiveness in terms of opioid prescriber behavior.

Task 2: Research the effectiveness of PDMP integration across Colorado as it relates to the opioid epidemic. This may include measuring specific health outcomes, as well as conducting cost/benefit analyses for statewide integration funding efforts.



2020

Task 1: Analyze the viability and appropriateness of user experience testing of available PDMP interfaces.

Task 2: Develop a plan to directly measure PDMP utilization in connection with controlled substance prescriptions.



2021

Task 1: Evaluate the risks and benefits of adding diagnostic information to PDMP data.

Task 2: Analyze the appropriateness of implementing new or additional unsolicited reports or clinical alerts for prescribers and pharmacies.

Task 3: Provide an analysis of costs for the future state of the technical architecture of the Colorado PDMP.



SB22-027

SB22-027 was enacted pursuant to the March 2021 PDMP audit report issued by the Office of the State Auditor (OSA)

- OSA report noted that the Colorado PDMP does not have the authority to provide unsolicited information to regulatory boards or law enforcement to allow them to investigate potentially unlawful behavior by prescribers or patients and recommended Colorado law be updated to allow for proactive information sharing with licensing boards and law enforcement.
- DORA agreed to work with the legislature regarding potential changes to Colorado law to allow unsolicited/proactive information sharing with licensing boards and law enforcement.
- SB22-027 required the PDMP Task Force to engage in a stakeholder engagement process to solicit feedback regarding this potential legislative change.



New Requirements in 2022

SB22-027 added a third requirement to the Annual Report in response to 2021 PDMP Audit

DORA Executive Director shall create a PDMP Task Force to develop a strategic plan to reduce prescription drug abuse in order to:

- 1) Examine issues, opportunities, and weaknesses of the program, including how personal information is secured in the program and whether inclusion of personal identifying information in the program and access to that information is necessary.
- 2) Make recommendations to the Executive Director on ways to make the program a more effective tool for practitioners and pharmacists in order to reduce prescription drug abuse in Colorado.
- 3) Evaluate and make recommendations to the Executive Director, after engaging in a stakeholder process, regarding balancing the program as a health-care tool with the enforcement of the Pharmacy Practice Act



2022

Task 1: Evaluate the effects of unsolicited reporting to licensing boards of licensees' prescribing activity.

Task 2: Evaluate the effects of allowing law enforcement access to PDMP data without requiring a subpoena or court order.

Stakeholders were overwhelmingly against a change to the law, citing the potential chilling effect on prescribers' willingness to prescribe to patients with chronic pain, on high doses of opioids, or on both opioids and benzodiazepines.



2023

Task 1: Evaluate impact to strengthen CO PDMP as a clinical decision support and public health tool by collecting and sharing fatal and/or non-fatal overdose information

Task 2: Evaluate implications of allowing practitioners with prescriptive authority who lack a DEA license to access CO PDMP



2024

Task 1: Evaluate the impact of integration on PDMP utilization and evaluate other factors or activities that could increase utilization

Task 2: Evaluate risks and benefits of requiring controlled substances administered or directly dispensed by practitioners to be reported to CO PDMP



CO PDMP Contacts and Links

DORA PDMP website: dpo.colorado.gov/PDMP

Legislative Reports: <u>www.leg.state.co.us/library/reports.nsf/reports.xsp</u> -Statutory Cite: 12-280-409(2)

State Administrator Email: PDMPINQR@state.co.us

State Administrator Phone: (303) 894-5957

Program Director: Dmitry Kunin

Program Analyst: Justin Wipf

PDMP Administrators: Gina Sanchez, Timothy White

